Hepatitis C: IMO-2125 Data will be presented at EASL

[Guest guest]

Hepatitis C: IMO-2125 Data will be presented at EASL

Idera Pharmaceuticals Announces IMO-2125 Data Presentation at the 46th Annual Meeting of the European Association for the Study of the LiverIdera Pharmaceuticals Inc. Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) today announced that data from its Phase 1 clinical trial of IMO-2125, its novel immune modulator for the treatment of chronic hepatitis C virus (HCV) infection, in treatment-naïve genotype 1 HCV patients will be presented at the 46th Annual Meeting of the European Association for the Study of the Liver (EASL) being held March 30 – April 3, 2011 in Berlin, Germany.The presentation entitled "IMO-2125 plus ribavirin gives substantial first-dose viral load reductions, cumulative antiviral effect, is well tolerated in naïve genotype 1 HCV patients: a Phase 1 trial,†D. Guyader, et al., will be made in a poster session entitled Viral Hepatitis C: Clinical (new compounds, resistance) on Saturday, April 2, 2011. The full

abstract (#1209) can now be accessed through the EASL website www.easl.eu.About IMO-2125IMO-2125, a Toll-like Receptor (TLR) 9 agonist, is a novel immune modulator being developed as a component of treatment for chronic hepatitis C virus (HCV) infection. IMO-2125 is designed to stimulate the immune system, causing the body to generate natural interferons and other antiviral cytokines. IMO-2125 has been evaluated in a Phase 1 clinical trial in null-responder HCV patients, defined as those who did not achieve a 2 log10 reduction with prior standard of care treatment, as monotherapy for 4 weeks and in a Phase 1 clinical trial in treatment-naïve HCV patients in combination with ribavirin for 4 weeks.

http://Hepatitis Cnewdrugs.blogspot.com/2011/03/hepatitis-c-imo-2125-data-will-be.html